ADCT
ADC Therapeutics SA
Overview
ADC Therapeutics designs and commercializes antibody-drug conjugates (ADCs) for cancer treatment. The company's approved product, ZYNLONTA, treats relapsed or refractory diffuse large B-cell lymphoma and is being studied in earlier treatment lines and other lymphomas.
ADC Therapeutics SA is a Healthcare company operating in Biotechnology with a $138.6M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 4, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-049 Q&A exchanges
- Q4 FY2025Earnings2026-03-107 Q&A exchanges
- Q3 FY2025Earnings2025-11-1010 Q&A exchanges
- Q2 FY2025Earnings2025-08-126 Q&A exchanges
- Q1 FY2025Earnings2025-05-1411 Q&A exchanges
- Q4 FY2024Earnings2025-03-2718 Q&A exchanges
- Q3 FY2024Earnings2024-11-099 Q&A exchanges
- Q2 FY2024Earnings2024-08-118 Q&A exchanges
- Q1 FY2024Earnings2024-05-0612 Q&A exchanges
- Q4 FY2023Earnings2024-03-1310 Q&A exchanges
- Q3 FY2023Earnings2023-11-0714 Q&A exchanges
- Q2 FY2023Earnings2023-08-0816 Q&A exchanges
- Q1 FY2023Earnings2023-05-0917 Q&A exchanges
- Q4 FY2022Earnings2023-02-2817 Q&A exchanges
- Q3 FY2022Earnings2022-11-0814 Q&A exchanges
- Q2 FY2022Earnings2022-08-0917 Q&A exchanges
- Q1 FY2022Earnings2022-05-093 Q&A exchanges
- Q4 FY2021Earnings2022-03-0315 Q&A exchanges
- Q3 FY2021Earnings2021-11-0220 Q&A exchanges
- Q2 FY2021Earnings2021-08-077 Q&A exchanges
- Q1 FY2021Earnings2021-05-094 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-04EPS— vs $-0.21—Rev— vs ——EODHD
- Q1 FY20262026-05-03EPS$-0.21 vs $-0.20-4.1%Rev$20.9M vs ——EODHD
- Q4 FY20252026-03-11EPS$-0.04 vs $-0.30+86.6%Rev$23.1M vs ——EODHD
- Q3 FY20252025-11-09EPS$-0.19 vs $-0.36+47.2%Rev$16.4M vs ——EODHD
- Q2 FY20252025-08-11EPS$-0.25 vs $-0.39+35.9%Rev$18.8M vs ——EODHD
- Q1 FY20252025-05-04EPS$-0.36 vs $-0.41+13.1%Rev$23.0M vs ——EODHD
- Q4 FY20242025-03-26EPS$-0.25 vs $-0.43+41.9%Rev$16.9M vs ——EODHD
- Q3 FY20242024-11-06EPS$-0.42 vs $-0.38-10.5%Rev$18.5M vs ——EODHD
- Q2 FY20242024-08-05EPS$-0.38 vs $-0.46+17.4%Rev$17.4M vs ——EODHD
- Q1 FY20242024-05-05EPS$-0.56 vs $-0.560.0%Rev$18.1M vs ——EODHD
- Q4 FY20232024-03-12EPS$-1.03 vs $-0.50-100.0%Rev$16.8M vs ——EODHD
- Q3 FY20232023-11-06EPS$-0.58 vs $-0.63+7.9%Rev$14.5M vs ——EODHD
- Q2 FY20232023-08-07EPS$-0.58 vs $-0.46-26.1%Rev$19.3M vs ——EODHD
- Q1 FY20232023-05-08EPS$-0.74 vs $-0.67-10.4%Rev$19.0M vs ——EODHD
- Q4 FY20222023-02-27EPS$-0.30 vs $-0.29-3.5%Rev$69.8M vs ——EODHD
- Q3 FY20222022-11-07EPS$-0.65 vs $-0.35-85.7%Rev$76.3M vs ——EODHD
- Q2 FY20222022-08-08EPS$-0.84 vs $-0.91+7.7%Rev$17.3M vs ——EODHD
- Q1 FY20222022-05-08EPS$-0.22 vs $-0.70+68.6%Rev$46.5M vs ——EODHD
- Q4 FY20212022-03-02EPS$-0.45 vs $-0.86+47.7%Rev$17.0M vs ——EODHD
- Q3 FY20212021-11-01EPS$-0.93 vs $-0.92-1.1%Rev$13.1M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-04 | — | $-0.21 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-03 | $-0.21 | $-0.20 | -4.1% | $20.9M | — | — | EODHD |
| Q4 FY2025 | 2026-03-11 | $-0.04 | $-0.30 | +86.6% | $23.1M | — | — | EODHD |
| Q3 FY2025 | 2025-11-09 | $-0.19 | $-0.36 | +47.2% | $16.4M | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-0.25 | $-0.39 | +35.9% | $18.8M | — | — | EODHD |
| Q1 FY2025 | 2025-05-04 | $-0.36 | $-0.41 | +13.1% | $23.0M | — | — | EODHD |
| Q4 FY2024 | 2025-03-26 | $-0.25 | $-0.43 | +41.9% | $16.9M | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-0.42 | $-0.38 | -10.5% | $18.5M | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $-0.38 | $-0.46 | +17.4% | $17.4M | — | — | EODHD |
| Q1 FY2024 | 2024-05-05 | $-0.56 | $-0.56 | 0.0% | $18.1M | — | — | EODHD |
| Q4 FY2023 | 2024-03-12 | $-1.03 | $-0.50 | -100.0% | $16.8M | — | — | EODHD |
| Q3 FY2023 | 2023-11-06 | $-0.58 | $-0.63 | +7.9% | $14.5M | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $-0.58 | $-0.46 | -26.1% | $19.3M | — | — | EODHD |
| Q1 FY2023 | 2023-05-08 | $-0.74 | $-0.67 | -10.4% | $19.0M | — | — | EODHD |
| Q4 FY2022 | 2023-02-27 | $-0.30 | $-0.29 | -3.5% | $69.8M | — | — | EODHD |
| Q3 FY2022 | 2022-11-07 | $-0.65 | $-0.35 | -85.7% | $76.3M | — | — | EODHD |
| Q2 FY2022 | 2022-08-08 | $-0.84 | $-0.91 | +7.7% | $17.3M | — | — | EODHD |
| Q1 FY2022 | 2022-05-08 | $-0.22 | $-0.70 | +68.6% | $46.5M | — | — | EODHD |
| Q4 FY2021 | 2022-03-02 | $-0.45 | $-0.86 | +47.7% | $17.0M | — | — | EODHD |
| Q3 FY2021 | 2021-11-01 | $-0.93 | $-0.92 | -1.1% | $13.1M | — | — | EODHD |
Source: EODHD. ADCT reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks ADCT's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 80% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.83 | $2.06 | +37.2% | +8.0% | +9.4% |
| Q4 FY2026 | $2.74 | $2.15 | +27.6% | +8.2% | +7.4% |
| Q3 FY2026 | $2.86 | $2.09 | +37.0% | +3.6% | +5.5% |
| Q2 FY2026 | $2.66 | $2.03 | +31.0% | +7.8% | +7.1% |
| Q1 FY2025 | $2.89 | $2.19 | +31.8% | +6.1% | +7.5% |
| Q4 FY2025 | $2.81 | $2.10 | +33.8% | +4.0% | +4.4% |
| Q3 FY2025 | $2.79 | $2.12 | +31.8% | +7.1% | +9.1% |
| Q2 FY2025 | $2.69 | $2.18 | +23.6% | +5.6% | +6.8% |
| Q1 FY2024 | $2.89 | $2.20 | +31.4% | -0.8% | +2.1% |
| Q4 FY2024 | $3.17 | $2.36 | +34.2% | -1.9% | -0.5% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Ameet MallikCEO1 yr 4 mo17 callsCurrentSample
CEO since 2025 • 1/4 beats (25%) • last guidance cut Q2 FY2026
- Jose CarmonaCFO1 yr 6 mo7 callsCurrentSample
CFO since 2024 • 5/8 beats (63%) • last guidance cut Q2 FY2026
- Peter J GrahamChief Legal Officer1 yr 4 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • last guidance cut Q3 FY2026
- Lisa Michelle KalleboChief Accounting Officer1 yr 6 mono recorded callsCurrentSample
OTHER_C_SUITE since 2024 • 3/8 beats (38%) • last guidance cut Q2 FY2026
- Mohamed ZakiChief Medical Officer1 yr 6 mo9 callsCurrentSample
OTHER_C_SUITE since 2024 • 6/8 beats (75%) • last guidance raise Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ADCT.
$ curl https://api.spokenalpha.com/v1/companies/ADCTFAQ
Frequently asked about ADCT
Where can I find ADC Therapeutics SA's (ADCT) earnings call transcripts?
Spoken Alpha indexes ADCT's earnings call transcripts at https://spokenalpha.com/companies/ADCT. Each call links to attributed speakers and parsed analyst Q&A. ADC Therapeutics SA's own investor relations page is at https://ir.adctherapeutics.com/.
When was ADC Therapeutics SA's most recent earnings call?
ADC Therapeutics SA (ADCT) held its most recent earnings call on 2026-05-04, covering fiscal Q1 2026.
What sector is ADCT in?
ADC Therapeutics SA (ADCT) operates in the Healthcare sector (Biotechnology industry).